Lates News

date
08/05/2025
Every AI fast news, Guojin Securities released a research report on May 7th, giving a buy rating to Antu Biological (603658.SH). The main reasons for the rating include: 1) The centralized procurement is driving industry reform, and the promotion of Luminescent High-Speed Machine is bringing market share improvement; 2) "Assembly line + molecular diagnosis + microbiological mass spectrometry" to create multiple platform growth; 3) The international market expansion has started, and new products continue to be unveiled. (Daily Economic News)
Latest
See all latestmore